DeLong Mark Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Mar 19, 2024
Insider Transaction Report
Form 4
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
- Sale
Common Stock
2024-03-18$56.90/sh−9,913$564,050→ 54,693 total
4 · Apellis Pharmaceuticals, Inc. · Filed Mar 19, 2024
Common Stock